forecast
发表于 2025-3-28 14:45:19
http://reply.papertrans.cn/43/4202/420174/420174_41.png
neolith
发表于 2025-3-28 18:57:41
http://reply.papertrans.cn/43/4202/420174/420174_42.png
Aggregate
发表于 2025-3-29 00:08:07
The Discovery of Velpatasvir (GS-5816): The Potent Pan-Genotypic Once-Daily Oral HCV NS5A Inhibitor ipasvir and the nonstructural 5B protein (NS5B) nucleotide inhibitor sofosbuvir (SOF), provided a major advancement in the treatment of individuals with chronic genotype 1 (GT1) HCV infection. Herein is described the discovery of velpatasvir (VEL, GS-5816), a pan-genotypic NS5A inhibitor with low pi
CT-angiography
发表于 2025-3-29 06:43:46
Discovery of Elbasvirand the NS3/4A protease inhibitor grazoprevir) for the treatment of adult patients with chronic hepatitis C virus genotype 1 or genotype 4 infection. The discovery of elbasvir (EBR) was the result of a concerted research effort within Merck’s newly formed External Basic Research (also, EBR) group an
确保
发表于 2025-3-29 11:08:24
http://reply.papertrans.cn/43/4202/420174/420174_45.png
Alveoli
发表于 2025-3-29 11:32:04
Evolution of HCV NS4B Inhibitorso 2016 led to the identification of different chemical classes targeting NS4B as effective anti-HCV agents, and some of them act by impairing AH2-mediated membranous web formation or RNA-binding property. This book chapter aims to discuss research published on NS4B inhibitors focusing on hit identif
interpose
发表于 2025-3-29 17:50:22
The Evolution of Clinical Trials for Hepatitis C-sought discovery of the causative agent, ranks as a landmark achievement of modern medicine. In the broadest sense, the international effort to address this global public health problem can be divided into an era of nonspecifically targeted therapy centering on interferon, a relatively brief “hybri
截断
发表于 2025-3-29 21:32:00
http://reply.papertrans.cn/43/4202/420174/420174_48.png
B-cell
发表于 2025-3-30 00:08:26
The Clinical Development of Sofosbuvir/Velpatasvir (SOF/VEL, Epclusa®) inhibitor, provides a highly efficacious, safe, and simple treatment regimen for patients with genotype 1–6 HCV infection. The clinical development program for SOF/VEL focused on generating safety and efficacy data across a broad range of patient populations to support a single treatment duration f
人造
发表于 2025-3-30 07:01:20
http://reply.papertrans.cn/43/4202/420174/420174_50.png